| Product NDC: | 0093-5247 |
| Proprietary Name: | Olanzapine |
| Non Proprietary Name: | Olanzapine |
| Active Ingredient(s): | 15 mg/1 & nbsp; Olanzapine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, ORALLY DISINTEGRATING |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0093-5247 |
| Labeler Name: | Teva Pharmaceuticals USA Inc |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA077243 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20120224 |
| Package NDC: | 0093-5247-65 |
| Package Description: | 5 BLISTER PACK in 1 CARTON (0093-5247-65) > 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (0093-5247-19) |
| NDC Code | 0093-5247-65 |
| Proprietary Name | Olanzapine |
| Package Description | 5 BLISTER PACK in 1 CARTON (0093-5247-65) > 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (0093-5247-19) |
| Product NDC | 0093-5247 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Olanzapine |
| Dosage Form Name | TABLET, ORALLY DISINTEGRATING |
| Route Name | ORAL |
| Start Marketing Date | 20120224 |
| Marketing Category Name | ANDA |
| Labeler Name | Teva Pharmaceuticals USA Inc |
| Substance Name | OLANZAPINE |
| Strength Number | 15 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Atypical Antipsychotic [EPC] |